EC approves Astellas’ PADCEV for urothelial cancer

The European Commission has authorised Astellas Pharma's PADCEV regimen for the first-line treatment of advanced urothelial cancer.

Aug 29, 2024 - 04:00

EC approves Astellas’ PADCEV for urothelial cancer

The European Commission has authorised Astellas Pharma's PADCEV regimen for the first-line treatment of advanced urothelial cancer.

Read the original article

Tags:

Previous Article

Navigator gains $100m in Series A funding for antibody therapeutics

Pfizer launches digital healthcare platform to streamline access

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

Vertex and CRISPR Therapeutics submit BLAs to FDA for exa-cel

Vertex and CRISPR Therapeutics submit BLAs to FDA for e...

Apr 4, 2023

Embracing digital solutions for enhanced patient care

Embracing digital solutions for enhanced patient care

Jun 30, 2024

STAT+: U.K. sequencing study surfaces new findings about tumor DNA

STAT+: U.K. sequencing study surfaces new findings abou...

Jan 10, 2024